Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14229453 | 0.87 | LTB4R2 (0.62) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL10032155 | 0.87 | CNR2 (0.73) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL1753870 | 0.86 | HDAC6 (0.58) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL10777558 | 0.84 | LTB4R2 (0.59) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL11050378 | 0.83 | HDAC6 (0.56) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL2187349 | 0.83 | HDAC6 (0.56) | LTB4R2CNR2HDAC6HDAC1PKM | |
| SCHEMBL10466773 | 0.83 | CNR2 (0.54) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL14200343 | 0.83 | CNR2 (0.54) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL22023396 | 0.83 | CNR2 (0.67) | LTB4R2CNR2RENHDAC6HDAC1 | |
| SCHEMBL11050338 | 0.83 | LMNA (0.54) | LTB4R2CNR2RENHDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8158617-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | LTB4R2 260/4885CNR2 27/4885REN 1401/4885 |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | LTB4R2 260/4885CNR2 27/4885REN 1401/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | LTB4R2 260/4885CNR2 27/4885REN 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.